Sudeep
Pharma Limited
(Formerly known as Sudeep Pharma Private Limited)

Date: 4th August 2026

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G Bandra Kurla Complex, Bandra (E), Mumbai – 400051
Scrip Symbol- SUDEEPPHRM

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400001
Scrip Code: 544619

Sub: Outcome of Board Meeting held on 4th August 2026

Ref: Regulation 30(6) of the SEBI Listing Regulations, 2015

Dear Sir/Ma'am,

This is to inform you that the Board of Directors of the Company, at its meeting held on Tuesday, 4th August 2026, has inter alia transacted the following businesses:

- Considered and approved the Unaudited Standalone & Consolidated Financial Results for the first quarter ended on 30th June 2026

The Board meeting commenced at 03:40 p.m. and concluded at 5:50 p.m.

You are requested to take the above information on record.

For Sudeep Pharma Limited

DIMPLE ASHWINBHAI MEHTA

Digitally signed by DIMPLE ASHWINBHAI MEHTA
DN: cn=DIMPLE ASHWINBHAI MEHTA, c=IN, st=Gujarat, o=Personal, title=8748, serialNumber=be901a7b4cfd5ff4b6e3310581e678582e8fcab3536586c4a365ba53eccbf1a6
Date: 2026.08.04 17:51:56 +05'30'

Dimple Mehta
Company Secretary & Compliance Officer
M. No.: F13184

ENCL: A/a

B S R and Co
Chartered Accountants

14th Floor, Central B Wing and North C Wing
Nesco IT Park 4, Nesco Center
Western Express Highway
Goregaon (East), Mumbai – 400 063, India
Telephone: +91 (22) 6257 1000
Fax: +91 (22) 6257 1010

Limited Review Report on unaudited consolidated financial results of Sudeep Pharma Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Sudeep Pharma Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Sudeep Pharma Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2026 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity",* issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement:

5. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. The Statement includes the financial results of two Subsidiaries which has not been reviewed, whose financial results reflect total revenues (before consolidation adjustments) of Rs. 1,139.55 lakhs, total net loss after tax and total comprehensive loss (before consolidation adjustments) of Rs. 49.12 lakhs, for the quarter ended 30 June 2026, as considered in the Statement. According to the information and explanations given to us by the Parent's management, this financial results is not material to the Group.

Principal Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

B S R and Co Chartered Accountants

Our conclusion is not modified in respect of this matter.

For **B S R and Co**
Chartered Accountants
Firm's Registration No.:128510W

Jeyur Shah
Partner
Membership No.: 045754
UDIN:26045754IACRMT8890

Vadodara
04 August 2026

Annexure I

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship
1	Sudeep Pharma Limited	Parent
2	Sudeep Nutrition Private Limited	Wholly owned subsidiary
3	Sudeep Pharma USA Inc.	Wholly owned subsidiary
4	Sudeep Pharma B.V	Wholly owned subsidiary
5	Sudeep Advanced Materials Private Limited	Wholly owned subsidiary
6	Nutrition Supplies & Services (Ireland) Limited	Step down subsidiary

B S R and Co * Chartered Accountants *

Sudeep Pharma Limited

Registered Office: 129/1/A, G.I.D.C. Estate Nandesari, Baroda-391340, Gujarat, India
Phone No.: +91 265 2840656, 7624095107
Website: www.sudeepgroup.com, Email ID: mail@sudeepgroup.com
CIN: L24231GJ1989PLC013141

Statement of unaudited consolidated financial results for the quarter ended 30 June 2026

(₹ in Lakhs)

Particulars	For quarter ended			For year ended
	30 June 2026 (Unaudited)	31 March 2026 (Audited) Refer note 5	30 June 2025 (Audited)	31 March 2026 (Audited)
Income				
I. Revenue from operations	15,827.05	18,233.87	12,491.75	64,225.80
II. Other income	544.54	642.47	515.85	2,858.54
III. Total Income (I+II)	**16,371.59**	**18,876.34**	**13,007.60**	**67,084.34**
IV. Expenses				
Cost of material consumed	6,880.57	7,113.74	5,762.90	26,950.46
Change in Inventories of finished goods and work-in-progress	(1,221.49)	(728.07)	(1,530.68)	(4,219.77)
Employee benefits expense	1,433.97	1,052.06	1,223.71	5,189.03
Finance costs	206.33	244.27	170.93	760.46
Depreciation and amortisation expense	400.08	388.44	325.15	1,480.85
Other expenses	3,242.87	4,536.60	2,648.39	14,115.87
Total Expenses (IV)	**10,942.33**	**12,607.04**	**8,600.40**	**44,276.90**
V. Profit before tax (III-IV)	**5,429.26**	**6,269.30**	**4,407.20**	**22,807.44**
VI. Tax Expenses:				
1. Current tax	1,227.67	1,270.03	1,233.94	5,091.53
2. Deferred tax	142.90	145.45	46.34	287.44
Total Tax Expenses (VI)	**1,370.57**	**1,415.48**	**1,280.28**	**5,378.97**
VII. Profit for the period (V-VI)	**4,058.69**	**4,853.82**	**3,126.92**	**17,428.47**
Other Comprehensive income/ (loss)				
A. Items that will not be reclassified to profit or loss				
Remeasurement of defined benefit liability / (asset)	11.22	24.98	(1.83)	1.05
Income tax relating to above items	(2.66)	(5.92)	0.20	0.10
B. Items that will be reclassified to profit or loss	-			
Exchange difference arising on translation of foreign operations	(13.77)	597.22	(281.81)	(123.67)
Other Comprehensive income/ (loss) for the period, net of tax (VIII)	**(5.21)**	**616.28**	**(283.44)**	**(122.52)**
IX. Total Comprehensive Income for the period (VII+VIII)	**4,053.48**	**5,470.10**	**2,843.48**	**17,305.95**
Profit attributable to :				
Owners of the Group	4,055.00	4,887.66	3,080.71	17,289.26
Non controlling interest	3.69	(33.84)	46.21	139.21
Profit for the period	**4,058.69**	**4,853.82**	**3,126.92**	**17,428.47**
Other Comprehensive income/ (loss) attributable to :				
Owners of the Group	(5.21)	616.28	(283.44)	(122.52)
Non controlling interest	-	-	-	-
Other Comprehensive income/ (loss) for the period	**(5.21)**	**616.28**	**(283.44)**	**(122.52)**
Total comprehensive income attributable to:				
Owners of the Group	4,049.79	5,503.94	2,797.27	17,166.74
Non controlling interest	3.69	(33.84)	46.21	139.21
Total comprehensive income for the period	**4,053.48**	**5,470.10**	**2,843.48**	**17,305.95**
X. Paid - up equity share capital (face value of INR 1 per share)				1,129.49
XI. Other Equity				87,204.31
XII. Earnings per Equity Share of Face Value of ₹ 1/- each (not annualised)				
Basic	3.59	4.38	2.84	15.50
Diluted	3.59	4.38	2.84	15.50
See accompanying notes to the unaudited consolidated financial results				

SUDEEP PHARMA LIMITED

B S R and Co Chartered Accountants

Sudeep Pharma Limited

Registered Office: 129/1/A, G.I.D.C. Estate Nandesari, Baroda-391340, Gujarat, India
Phone No.: +91 265 2840656, 7624095107
Website: www.sudeepgroup.com, Email ID: mail@sudeepgroup.com
CIN: L24231GJ1989PLC013141

Statement of unaudited consolidated Segment information for the quarter ended 30 June 2026

(₹ in Lakhs)

Particulars	For quarter ended			For year ended
	30 June 2026 (Unaudited)	31 March 2026 (Audited) Refer note 5	30 June 2025 (Audited)	31 March 2026 (Audited)
1. Segment revenue (Reconciliation with revenue from operations)				
(a) External revenues				
(i) Pharmaceutical, food and nutrition	10,841.37	9,009.94	8,298.68	36,263.91
(ii) Speciality ingredients	4,985.68	9,223.93	4,193.07	27,961.89
(b) Inter - segment revenues	209.09	300.33	127.94	847.15
	16,036.14	**18,534.20**	**12,619.69**	**65,072.95**
Inter-segment revenue	(209.09)	(300.33)	(127.94)	(847.15)
	15,827.05	**18,233.87**	**12,491.75**	**64,225.80**
2. Segment result before other income, finance costs and tax expense (Reconciliation with profit for the period)				
(i) Pharmaceutical, food and nutrition	4,185.79	2,939.68	2,832.04	12,065.36
Depreciation and amortisation	(183.34)	(180.03)	(174.83)	(713.76)
(A)	4,002.45	2,759.65	2,657.21	11,351.60
(ii) Speciality ingredients	1,305.34	3,319.86	1,555.39	10,124.85
Depreciation and amortisation	(216.74)	(208.41)	(150.32)	(767.09)
(B)	1,088.60	3,111.45	1,405.07	9,357.76
Total Segment results (A+B)	**5,091.05**	**5,871.10**	**4,062.28**	**20,709.36**
Net unallocated income	544.54	642.47	515.85	2,858.54
Finance costs	(206.33)	(244.27)	(170.93)	(760.46)
Profit before tax	**5,429.26**	**6,269.30**	**4,407.20**	**22,807.44**
Tax expense	(1,370.57)	(1,415.48)	(1,280.28)	(5,378.97)
Profit for the period	**4,058.69**	**4,853.82**	**3,126.92**	**17,428.47**
3. Segment assets and segment liabilities				
(i) Pharmaceutical, food and nutrition	78,691.31	72,721.08	59,289.20	72,721.08
(ii) Speciality ingredients	46,307.39	44,373.75	32,744.11	44,373.75
	1,24,998.70	1,17,094.83	92,033.31	1,17,094.83
Unallocated	72.93	392.82	192.25	392.82
Total Segment Assets	**1,25,071.63**	**1,17,487.65**	**92,225.56**	**1,17,487.65**
(i) Pharmaceutical, food and nutrition	24,581.60	21,788.35	16,659.26	21,788.35
(ii) Speciality ingredients	5,199.22	4,851.42	4,734.60	4,851.42
	29,780.82	26,639.77	21,393.86	26,639.77
Unallocated	1,453.06	1,038.69	1,438.62	1,038.69
Total Segment Liabilities	**31,233.88**	**27,678.46**	**22,832.48**	**27,678.46**

SUDEEP PHARMA LIMITED

B S R and Co * Chartered Accountants *

Key standalone financial information:

(₹ in Lakhs)

Particulars	For quarter ended			For year ended
	30 June 2026 (Unaudited)	31 March 2026 (Audited) Refer note 5	30 June 2025 (Unaudited)	31 March 2026 (Audited)
Total income	11,548.36	8,978.62	8,679.38	37,700.94
Profit before tax	4,540.75	3,474.31	3,382.65	14,509.69
Profit after tax	3,382.85	2,576.56	2,520.49	10,758.07

SUDEEP PHARMA LIMITED

B S R and Co Chartered Accountants

Sudeep Pharma Limited

Registered Office: 129/1/A, G.I.D.C. Estate Nandesari, Baroda-391340, Gujarat, India
Phone No.: +91 265 2840656, 7624095107
Website: www.sudeepgroup.com, Email ID: mail@sudeepgroup.com
CIN: L24231GJ1989PLC013141

Notes:

1 The above unaudited consolidated financial results of Sudeep Pharma Limited (the"Company") and its subsidiaries (together referred to as the "Group") have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the company in their meetings held on 04 August 2026. The Statutory Auditors of the Company have carried out Limited review of the said unaudited consolidated financial results.

2 The above unaudited consolidated financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim financial reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 (the "Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended (Listing Regulations).

3 The Company's equity shares were listed on the National Stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) on 28 November 2025. The Company has received an amount of INR 8,833.59 lakhs as net proceeds which is summarised as follows.

Particulars	**Amount (in INR lakhs)**
Gross Proceeds of the fresh issue of equity shares	9,500.00
(Less) Estimated offer related expenses to be borne by the Company*	666.41
Net Proceeds	**8,833.59**

*The Company has estimated ₹ 6,290.24 lakhs as IPO related expenses and allocated such expenses between the Company ₹ 666.41 lakhs and selling shareholders ₹ 5,623.83 lakhs in proportion to the equity shares allotted to the public as fresh issue by the Company and under offer for sale by selling shareholders respectively. As at 30 June 2026, the total amount attributable to the Company amounting to ₹ 666.41 lakhs has been adjusted to securities premium.

The utilisation of net proceeds from IPO is summarised below:

Sr. No.	**Objects of the issue**	**Net IPO Proceeds to be utilised**	**Utilisation of net IPO proceeds up to 30 June 2026**	**Unutilised net IPO proceeds as on 30 June 2026***
1	Capital expenditure towards procurement of machinery for our production line located at Nandesari Facility I	7,581.40	35.77	7,545.63
2	General corporate purposes	1,252.19	1,252.19	-
	Net Proceeds	8,833.59	1,287.96	7,545.63

* As at 30 June 2026 these unutilized net IPO proceeds, pending deployment towards the object, are kept as term deposits in bank.

4 In accordance with 'Ind AS 108 - Operating Segments', the Group operates in two operating segments i.e. '(i) Pharmaceutical, food and nutrition' and '(ii) Speciality ingredients'

5 Figures for the quarter ended 31 March 2026 as reported in the statement are the balancing figures between the audited figures in respect of the full financial year and the limited reviewed year to date period ended 31 December 2025.

6 The Group, through its subsidiary, entered into binding share purchase agreement with Nutrition Supplier & Services (Ireland) Limited (NSS), on 09 April 2025 for acquisition of 85% equity interest, with a purchase price of Rs. 12,857.63 Lakhs. Pursuant to completion of the acquisition, NSS became a step-down Subsidiary of Group with effect from May 22, 2025.

The Group has completed final purchase price allocation (" PPA") during the quarter ended 30 June 2026 on the fair value of net assets of the NSS acquired in accordance with Ind AS 103 "Business Combination with help of external experts. Consequently, the values of assets and liabilities acquired has been accounted on fair value and the resultant Goodwill has been recognized in unaudited consolidated financial results.

7 The unaudited consolidated financial results for the quarter ended 30 June 2026 are also being made available on the Stock Exchange websites bseindia.com and www.nseindia.com and on the Company's website: www.sudeepgroup.com.

B S R and Co
Chartered Accountants

For and on behalf of Board of Directors of
Sudeep Pharma Limited

Bhayani

Sujit J Bhayani
Managing Director
DIN : 01767427
Place: Vadodara
Date: 04 August 2026

SUDEEP PHARMA LIMITED

B S R and Co
Chartered Accountants

14th Floor, Central B Wing and North C Wing
Nesco IT Park 4, Nesco Center
Western Express Highway
Goregaon (East), Mumbai – 400 063, India
Telephone: +91 (22) 6257 1000
Fax: +91 (22) 6257 1010

Limited Review Report on unaudited standalone financial results of Sudeep Pharma Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Sudeep Pharma Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Sudeep Pharma Limited (hereinafter referred to as "the Company") for the quarter ended 30 June 2026 ("the Statement").

   Attention is drawn to the fact that the figures for the corresponding quarter ended 30 June 2025, as reported in the Statement have been approved by the Company's Board of Directors, but have not been subjected to review.

2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity"*, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it

Principal Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

contains any material misstatement.

For **B S R and Co**
Chartered Accountants
Firm's Registration No.:128510W

Jeyur Shah
Partner
Membership No.: 045754
UDIN:26045754SYNQMK5065

Vadodara
04 August 2026

Sudeep Pharma Limited

Registered Office: 129/1/A, G.I.D.C. Estate Nandesari, Baroda-391340, Gujarat, India
Phone No.: +91 265 2840656, 7624095107
Website: www.sudeepgroup.com, Email ID: mail@sudeepgroup.com
CIN: L24231GJ1989PLC013141

Statement of unaudited standalone financial results for the quarter ended 30 June 2026

Particulars	For quarter ended			For year
	30 June 2026 (Unaudited)	31 March 2026 (Audited) Refer note 5	30 June 2025 (Unaudited) Refer note 5	31 March 2026 (Audited)
Income				
I. Revenue from operations	10,568.33	8,016.71	8,017.42	33,850.54
II. Other income	980.03	961.91	661.96	3,850.40
III. Total Income (I+II)	**11,548.36**	**8,978.62**	**8,679.38**	**37,700.94**
IV. Expenses				
Cost of material consumed	4,832.05	3,786.06	3,283.49	15,683.77
Change in Inventories of finished goods and work-in-progress	(505.77)	(1,688.85)	(640.27)	(4,550.35)
Employee benefits expense	746.03	598.88	738.48	2,895.05
Finance costs	176.05	196.85	143.69	606.62
Depreciation and amortisation expense	182.64	179.32	174.83	710.97
Other expenses	1,576.61	2,432.05	1,596.51	7,845.19
Total Expenses (IV)	**7,007.61**	**5,504.31**	**5,296.73**	**23,191.25**
V. Profit before tax (III-IV)	**4,540.75**	**3,474.31**	**3,382.65**	**14,509.69**
VI. Tax Expenses:				
1. Current tax	985.56	718.57	819.64	3,432.30
2. Deferred tax	172.34	179.18	42.52	319.32
Total Tax Expenses (VI)	**1,157.90**	**897.75**	**862.16**	**3,751.62**
VII. Profit for the period (V-VI)	**3,382.85**	**2,576.56**	**2,520.49**	**10,758.07**
Other Comprehensive income/(loss)				
A. Items that will not be reclassified to profit or loss				
Remeasurement of defined benefit liability / (asset)	9.21	20.38	1.41	(3.54)
Income tax relating to above items	(2.32)	(5.13)	(0.36)	0.89
Other Comprehensive income/(loss) for the period, net of tax (VIII)	**6.89**	**15.25**	**1.05**	**(2.65)**
IX. Total Comprehensive Income for the period (VII+VIII)	**3,389.74**	**2,591.81**	**2,521.54**	**10,755.42**
X. Paid - up equity share capital (face value of ₹ 1/- per share)				1,129.49
XI. Other Equity				77,471.43
XII. Earnings per Equity Share of Face Value of ₹ 1/- each (not annualised)				
Basic	3.00	2.31	2.29	9.65
Diluted	3.00	2.31	2.29	9.65
See accompanying notes to the unaudited standalone financial results				

SUDEEP PHARMA LIMITED

B S R and Co Chartered Accountants

Sudeep Pharma Limited
Registered Office: 129/1/A, G.I.D.C. Estate Nandesari, Baroda-391340, Gujarat, India
Phone No.: +91 265 2840656, 7624095107
Website: www.sudeepgroup.com, Email ID: mail@sudeepgroup.com
CIN: L24231GJ1989PLC013141

Notes:

1. The above unaudited standalone financial results of Sudeep Pharma Limited (the"Company") have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 04 August 2026.The Statutory Auditors of the Company have carried out Limited review of the said unaudited standalone financial results.
2. The above unaudited standalone financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim financial reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 (the "Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended (Listing Regulations).
3. The Company's equity shares were listed on the National Stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) on 28 November 2025. The Company has received an amount of INR 8,833.59 lakhs as net proceeds which is summarised as follows.

Particulars	Amount (in INR lakhs)
Gross Proceeds of the fresh issue of equity shares	9,500.00
(Less) Estimated offer related expenses to be borne by the Company*	666.41
Net Proceeds	**8,833.59**

*The Company has estimated ₹ 6,290.24 lakhs as IPO related expenses and allocated such expenses between the Company ₹ 666.41 lakhs and selling shareholders ₹ 5,623.83 lakhs in proportion to the equity shares allotted to the public as fresh issue by the Company and under offer for sale by selling shareholders respectively. As at 30 June 2026, the total amount attributable to the Company amounting to ₹ 666.41 lakhs has been adjusted to securities premium.

The utilisation of net proceeds from IPO is summarised below:

Sr. No.	Objects of the issue	Net IPO Proceeds to be utilised	Utilisation of net IPO proceeds up to 30 June 2026	Unutilised net IPO proceeds as on 30 June 2026*
1	Capital expenditure towards procurement of machinery for our production line located at Nandesari Facility I	7,581.40	35.77	7,545.63
2	General corporate purposes	1,252.19	1,252.19	-
	Net Proceeds	8,833.59	1,287.96	7,545.63

* As at 30 June 2026 these unutilized net IPO proceeds, pending deployment towards the object, are kept as term deposits in bank.

4. In accordance with 'Ind AS 108 - Operating Segments', the Company operates in single business segment i.e. 'Pharmaceutical, food and nutrition'. Segment information has been provided in unaudited consolidated financial results.
5. Figures for the corresponding quarter ended 30 June 2025 as reported in the statement have been approved by the Company's Board of Directors but have not been subjected to limited review since the requirement of submission of quarterly standalone financial results is applicable on listing of equity shares of the Company from the quarter ended 30 September 2025.

   Figures for the quarter ended 31 March 2026 as reported in the statement are the balancing figures between the audited figures in respect of the full financial year and the limited reviewed year to date period ended 31 December 2025.
6. The unaudited standalone financial results for the quarter ended 30 June 2026 are also being made available on the Stock Exchange websites bseindia.com and www.nseindia.com and on the Company's website: www.sudeepgroup.com.

B S R and Co
Chartered Accountants

For and on behalf of Board of Directors of
Sudeep Pharma Limited

Sujit J Bhayani
Managing Director
DIN : 01767427
Place: Vadodara
Date: 04 August 2026

SUDEEP PHARMA LIMITED